Article

Novel Immune Drug Combination Induces Tumour Microenvironment Remodelling and Reduces the Dosage of Anti-PD-1 Antibody

2024-10-01

Abstract excerpt

<title>Abstract</title> <p>Immune checkpoint inhibitors (ICIs) are effective in clinical settings; however, they present immune-related adverse effects and financial burden. Although dose reduction of ICIs may mitigate these limitations, it could compromise therapeutic efficacy. The combination of poly(I:C) and LAG-3-Ig is an effective immune adjuvant for cancer immunotherapy. Using these two adjuvants combined w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1cca92a7-9666-5cea-9039-33af90161c3c
DOI: 10.21203/rs.3.rs-4952779/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel Immune Drug Combination Induces Tumour Microenvironment Remodelling and Reduces the Dosage of Anti-PD-1 AntibodyDOI 10.21203/rs.3.rs-4952779/v1Read

Advances in cancer immunotherapy: historical perspectives, current developments, and future directionsSemantic proximity Read

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read

Anti-PD-1-iRGD Peptide Conjugate Boosts Antitumor Efficacy via Engagement Augmentation and Penetration Enhancement of T cellsSemantic proximity Read

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read

PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.Semantic proximity Read

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumorsSemantic proximity Read

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read

Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity Read

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read

Intra-tumoral injection of caerin 1.1 and 1.9 peptides in vaccinated TC-1 tumour bearing mice with PD-1 blockade modulates macrophage heterogeneity and the activation of CD8+ T cells in the tumour microenvironmentSemantic proximity Read